Amicus Therapeutics Overview

  • Founded
  • 2002
Founded
  • Status
  • Public
  • Employees
  • 483
Employees
  • Stock Symbol
  • FOLD
Stock Symbol
  • Investments
  • 4
  • Share Price
  • $10.48
  • (As of Friday Closing)

Amicus Therapeutics General Information

Description

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Currently, the company is focused on treating Fabry Disease with its treatment Galafold and developing additional therapies for Fabry patients. Amicus has also received breakthrough therapy designation that allows it to deploy a therapy for Pompe Disease in late-stage patients.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 1 Cedar Brook Drive
  • Cranbury, NJ 08512
  • United States
+1 (609) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Amicus Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.48 $10.35 $6.25 - $25.39 $2.77B 264M 4M -$1.07

Amicus Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 5,948,465 5,948,465 2,172,957 1,567,822
Revenue 260,886 260,886 182,237 91,245
EBITDA (246,209) (246,209) (342,512) (332,932)
Net Income (276,852) (276,852) (356,388) (348,995)
Total Assets 886,520 886,520 850,207 789,951
Total Debt 441,730 441,730 210,225 321,740
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Amicus Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amicus Therapeutics‘s full profile, request access.

Request a free trial

Amicus Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Amicus Therapeutics‘s full profile, request access.

Request a free trial

Amicus Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering medicines for peop
Pharmaceuticals
Cranbury, NJ
483 As of 2020
00000
00000000 00000

0000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
0000 000000000
Plymouth Meeting, PA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000

000000 0

iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commo
0000 000000000
San Diego, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amicus Therapeutics Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Harmony Biosciences Formerly VC-backed Plymouth Meeting, PA 000 00000 00000000 00000
000000 00000000000 Formerly VC-backed San Diego, CA 00 00000 000000000 00000
0000000 Venture Capital-Backed Groningen, Netherlands 0 00000 0000000000 0 00000
00000 000000000000 Formerly VC-backed Burnaby, Canada 000 0000 00000000 0000
00000000 Formerly VC-backed Rockville, MD 0 000.00 00000000 000.00
You’re viewing 5 of 15 competitors. Get the full list »

Amicus Therapeutics Executive Team (19)

Name Title Board Seat Contact Info
John Crowley JD Chief Executive Officer & Chairman
Daphne Quimi Chief Financial Officer, Finance
Bradley Campbell Chief Operating Officer, Operations & Board Member
Samantha Prout Chief Accounting Officer, Accounting & Controller, Finance
Jeff Castelli Ph.D Chief Development Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Amicus Therapeutics Board Members (18)

Name Representing Role Since
Bradley Campbell Amicus Therapeutics Chief Operating Officer, Operations & Board Member 000 0000
Burke Whitman Amicus Therapeutics Board Member 000 0000
Craig Wheeler Amicus Therapeutics Board Member 000 0000
Glenn Sblendorio Self Board Member 000 0000
John Crowley JD Amicus Therapeutics Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Amicus Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amicus Therapeutics Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 20-Sep-2018 000000000000000000 00000 Biotechnology 0000 0000000 00
000000 05-Jul-2016 000000000000000000 000.00 Biotechnology 0000 0000000 00
00000000 30-Sep-2015 000000000000000000 00000 Pharmaceuticals 0000 0000000 00
Callidus Biopharma 21-Nov-2013 Merger/Acquisition 0000 Drug Delivery 0000 0000000 00
To view Amicus Therapeutics’s complete acquisitions history, request access »